univers coverag
calendar event
fda adcom neurolog devic panel medic devic
medic meet american academi implant dentistri american societi head
 neck radiolog emerg nurs associ european societi paediatr
endocrinolog asnd european organis research treatment cancer
iph feder surgeri obes metabol disord north american spine
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
specialist highlight challeng inpati solut demand pt
bottom line recent held puls call two medacorp specialist discuss
on-going sale process athn call specialist highlight
signific challeng inpati platform instal process sever facil
may led litig settlement specialist highlight electron
medic record market demand slow dead plan might
consid buy athn complianc challeng might materi plan would
access payment rate inform compet plan could caus doctor
select anoth practic manag vendor believ headwind steadi
declin book growth may caus potenti acquir athn re-
consid bid price deal go near term athn could trade
rang point valuat would becom attract view without deal
believ athn would still commit grow adjust oper margin view
high recur revenu rate attract reduc pt
athn seem want sell
execut face lucr compens sale occur
issu athn inpati solut may contributor delay sale process
market demand dead new sale emr shift focu oper leverag
viabl bidder unlik move market elliott remain viabl acquir
averag dcf price-to-earnings
bottom line morn alexion announc reach agreement acquir
privat clinic stage biotech compani syntimmun cash
potenti futur mileston payment posit transact competit
strateg financi reason ad revenu forecast alexion
materi alter valuat time product potenti contribut could increas
materi importantli cost entri promis neonat fc receptor fcrn
categori rel modest total consider cap ultim
signific synergi rest alexion portfolio incorpor revenu contribut
cost acquisit alter near-term revenu earn outlook valuat
stage assign probabl approv lead candid
lead indic total peak sale potenti non-risk adjust reiter
outperform rate price target
syntimmun provid pipelin boost backload deal term
fcrn competit field one clearli differenti
posit transact strateg financi oper reason well
updat model today news ad modest revenu forecast
begin
revenu mm ep exclud option expens
stock reaction lack extens c-code unwarr
bottom line believ stock move yesterday overreact
provis question potenti extend c-code durat current
year alway contain possibl make hous version opioid bill final
one heron still c-code advantag outpati set pacira
mp exparel believ data heron gener demonstr
stronger clinic profil support greater use vs exparel stock trade level
seen sinc releas posit phase data june reiter op rate
recommend buy weak
impli sale impact base stock reaction unwarr view
learn robot navig nass day
bottom line attend north american spine societi nass meet take place
lo angel ca sept provid impress day discussions/
meet around navig robot platform -- -a key area focu year confer overal
main impress grow number compani op op mp
work talk evolv close-to-launch robot ambit
view mp /mazor op like remain two front-runn -- -at least
near-to-intermedi term -- -in categori clearli pick steam gain surgeon
interest tidbit learn mdt/mazor discuss
think comment posit robot categori whole especi
view follow reason
rosa platform still pend approv could avail limit launch late
answer robot includ exclus just-sign relationship brainlab plu eventu
spine applic orthotaxi orthoped robot platform
 methodolog dcf analysi revenu multipl dr tgr
bottom line zlab announc data recent present chines societi clinic
oncolog meet last weekend highlight updat efficaci result phase ii
studi brivanib hepatocellular carcinoma pk data niraparib
importantli zlab announc plan evalu brivanib combin therapi
view reason path forward given mechanist similar brivanib
drug demonstr compel earli data combin lenvatinib
bevacizumab evolv landscap believ progress toward combin
therapi continu view brivanib upsid vs consensu expect link call
comeback emerg china landscap offer brivanib chanc given disappoint
develop histori brivanib investor focu later stage de-risk area zlab pipelin
includ niraparib oncolog optun oncolog omadacyclin infecti diseas pt
phase ii brivanib data demonstr anti-tumor activ manag safeti profil plan pursu
niraparib pk data show consist profil chines ovarian cancer patient
upcom catalyst includ niraparib approv subsequ commerci launch hong kong
gag claus expect new increas price
bottom line believ passag two gag claus bill materi
impact op esrx mp earn express script inform us
use gag claus contract view bill repres increment
step washington take reduc drug price promot greater price transpar
take up-front risk better control econom preeclampsia
bottom line recal alreadi option opt-in sever preeclampsia
orphan diseas area pipelin although take greater up-front clinic risk
said base initi review view deal interest up-front
payment plu cost complet studi given better control
clinic trial execut slow far asset could address high unmet need
addit get better econom longer term revis deal pay mid-singl
royalti velo instead high-singl digit royalti previous
bottom line updat data cmta studi demonstr import
improv move protocol treatment flare-up studi flexibl
treat flare-up symptom allow patient act sooner treat longer time
need think mitig excess bone growth led compani
recent miss bogey reduct first analysi part extens studi
importantli believ bode well compani on-going registr move trial
readout interim analys reiter op
state concern unlik derail cvs-aet merger deal approv like
bottom line continu believ cvs-aet merger gain regulatori approv
believ unlik concern highlight ny depart financi servic
repres credibl threat deal passag follow doj recent approv ci-esrx
merger link mani news report doj close approv cvs-aet deal
believ deal approv like state sue block merger -- even
approv doj accord discuss medacorp kol likelihood
extrem low continu expect horizont concern part link requir divestitur
would reduc merit state case block merger
bottom line view resolut mm settlement doj investig hma
legaci hospit clear event remov uncertainti leverag plan reserv
oper turnaround margin expans opportun continu offer posit
invest thesi settlement relat on-going investig hma medicar medicaid
tricar anti-kickback law violat prior acquisit
awar investig reserv potenti settlement establish liabil
conting valu right cvr process
bottom line lpnt announc ceo carpent retir post merger rcch
replac david dill view merger remain track close year-end
mr carpent remain merg organ board post retir unclear given
news whether rcch chairman ceo marti rash cfo mike browder remain key role
integr compani
initi oncolog op loxo bgne tsro
survey confirm bullish view adcetri frontlin hl reiter op
data show impress durabl toler ret nsclc
posit phoenix data igan ckd increas pt
 methodolog dcf discount rate termin gr rate
icer highlight dupi advantag hi-e asthma costli budget-
averag price-to-earnings p/ dcf methodolog
obsv nolasiban oral oxytocin receptor antagonist assist
nolasiban target ivh market larg grow need treatment
implant phase data demonstr direct improv
pregnanc rate day day pregnanc show stat sig improv
pool data
believ data encourag may even suffici approv eu
along posit sub-group analysi ph
look manag provid greater regulatori clariti requir approv
us eu
believ risk-reward skew upsid ahead upcom catalyst
addit look live birth rate data implant posit
go long way improv commerci potenti
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es also
ini tumor cohort
initi approv tazemetostat could es drug demonstr
respons rate diseas control rate rare sarcoma littl
updat data expect esmo compani expect present durat
respons data key fda assssment respons rate data
regulatori file expect mild delay origin guidanc
compani resolv partial clinic hold
es small indic modest fundament valu peak us revenu
risk-adjust npv probabl success approv could
help de-risk larger opportun especi light recent partial clinic hold
potenti safeti regulatori concern
esmo abstract releas oct edt
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
fda adcom neurolog devic panel medic devic
fda adcom vaccin relat biolog product
state connecticut cvs-aet hear
fda adcom anesthet analges drug product
fda adcom joint gastrointestin drug drug safeti risk
pdufa dupix moder sever asthma adult adolesc
fda adcom scienc board fda
fda adcom endocrinolog metabol drug
fda adcom joint psychopharmacolog drug drug safeti risk
pdufa revefenacin lama copd
epo decis ip tsro
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
feder surgeri obes metabol disord
american academi implant dentistri
american societi head neck radiolog
european societi paediatr endocrinolog asnd
european organis research treatment cancer iph
american societi bone miner research asnd cmta
american congress rehabilit medicin
american colleg emerg physician
european associ studi diabet
american societi clinic patholog
infecti diseas societi america
foundat prader-willi research zfgn
american colleg gastroenterolog
american colleg chest physician
european colleg neuropsychopharmacolog
congress neurolog surgeon
american societi reproduct medicin
american academi otolaryngolog head neck surgeri aao-hnsf annual
american committe treatment research multipl sclerosi
intern societi technolog arthroplasti
american societi dermatolog surgeri
european associ neuro-oncolog
american associ blood bank
american societi anesthesiologist
european associ nuclear medicin
european societi gene cell therapi
american societi human genet arql
american colleg dentist
european associ cardiothorac surgeri
european societi medic oncolog adap
american colleg rheumatolog
canadian associ pediatr health centr
colleg american pathologist
american societi therapeut radiolog oncolog
american academi child adolesc psychiatri
american societi nephrolog kidney week
clinic trial alzheim diseas
american academi physic medicin rehabilit
american academi ophthalmolog
american academi periodontolog
go live az
model model recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
perform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 medacorp survey highlight driver headwind ali pt outperform
 vyxeo survey suggest outpati usag grow outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
 survey confirm bullish view adcetri frontlin hl reiter op pt
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
